Secrecy: A demon of gene therapy’s past bedevils its future
By Eric B. Kmiec,
Stat
| 07. 11. 2022
Twenty-three years ago, the field of gene therapy was bursting with the promise of breakthrough treatments. Then it was almost instantly derailed by the death of an 18-year-old clinical trial volunteer named Jesse Gelsinger after he received a genetically engineered virus that had been developed to treat his rare liver condition.
An FDA investigation revealed that the principal investigator and/or the team running the gene therapy trial at the University of Pennsylvania failed to disclose that before Gelsinger was treated, other patients had experienced alarming side effects and that monkeys administered the same engineered virus had died. The incident, coupled with dangerous outcomes involving other gene therapy treatments, had a chilling effect on the field and investors backed away.
Today, new approaches to gene therapy that include advances driven by CRISPR gene editing tools are raising hopes of a gene therapy revival. There are potential breakthroughs in the pipeline, including treatments for different types of cancer and sickle cell disease.
I’m concerned that gene therapy 2.0 is at risk of making the same mistakes that plagued the 1.0... see more
Related Articles
By Lisa C. Ikemoto, Los Angeles Times | 07.07.2022
A few days after the Supreme Court overturned Roe vs. Wade, Boston IVF, a fertility company with centers in six states, posted a statement that speaks to the havoc this decision will wreak not just for abortions, but for...
Several new opinion polls on human biotechnology issues have recently come to our attention and two of them are discussed here. As is all too typical of polling on these complex matters, it is not clear that respondents were aware of, or informed about, key background information that would shield them from drawing false conclusions, as discussed below. (For summaries of these and older opinion polls on topics related to heritable human genome editing and cloning or genetically modifying animals...
By Antonio Regalado, MIT Technology Review | 07.12.2022
A volunteer in New Zealand has become the first person to undergo DNA editing in order to lower their blood cholesterol, a step that may foreshadow wide use of the technology to prevent heart attacks.
The experiment, part of a...
By Carissa Wong, New Scientist | 07.01.2022
Photo by CDC on Unsplash
A new form of the genome-editing technique CRISPR could provide a more accurate way to edit mutations that cause genetic diseases. The approach, which was tested in fruit flies, fixes a genetic mutation on one...